SciClone Increases Stock Repurchase Program

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that its board of directors has approved an increase of approximately $10.5 million to the Company's stock repurchase program. The increase brings the total authorized since the program's inception in October 2011 to approximately $30.5 million. The total amount repurchased to date is approximately $10.5 million. "We are pleased with the execution of our share repurchase program and we continue to believe that the value of our Company is not reflected in our current share price. We have confidence in our ability to deliver strong financial results and achieve significant growth of our China-focused business," said Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer. "Today, we rank among a top handful of companies that have the critical mass of products, sales force and commercial infrastructure needed to manage the challenges, and capitalize on the opportunities, to succeed in the China market. We believe that SciClone's business prospects for 2012 are bright, and that we have the potential to deliver another strong year of growth and financial performance."